Apellis Pharmaceuticals Inc.(APLS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

APLS Apellis Pharmaceuticals Inc.

Trading 03-20 14:46:39 EDT

17.79

-0.18

-1.00%

High18.09	Low17.74	Vol703.50K
Open17.96	D1 Closing17.97	Amplitude1.95%
Mkt Cap2.27B	Tradable Cap1.39B	Total Shares127.83M
T/O12.61M	T/O Rate0.90%	Tradable Shares78.12M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"APLS","market":"US","secType":"STK","nameCN":"Apellis Pharmaceuticals Inc.","latestPrice":17.79,"timestamp":1774032398112,"preClose":17.97,"halted":0,"volume":703501,"delay":0,"changeRate":-0.010016694490818014,"floatShares":78119932,"shares":127829909,"eps":0.172407,"marketStatus":"Trading","change":-0.18,"latestTime":"03-20 14:46:39 EDT","open":17.96,"high":18.09,"low":17.74,"amount":12609224.092534,"amplitude":0.019477,"askPrice":17.81,"askSize":400,"bidPrice":17.77,"bidSize":201,"shortable":3,"etf":0,"ttmEps":0.172407,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1774036800000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1510203600000,"exchange":"NASDAQ","adjPreClose":17.97,"preHourTrading":{"tag":"盘前","latestPrice":17.9,"preClose":17.97,"latestTime":"09:29 EDT","volume":1525,"amount":27280.8165,"timestamp":1774013382063,"change":-0.07,"changeRate":-0.003895,"amplitude":0.010017},"postHourTrading":{"tag":"盘后","latestPrice":17.97,"preClose":17.97,"latestTime":"17:51 EDT","volume":32599,"amount":585803.63,"timestamp":1773957073334,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.360478,"optionData":{"bulkOrders":[{"symbol":"APLS","call":false,"expireDate":1776398400000,"strike":"19.0","timestamp":1774032109457,"price":1.5,"volume":1500,"amount":225000,"type":"-"},{"symbol":"APLS","call":false,"expireDate":1773979200000,"strike":"20.0","timestamp":1774032109457,"price":2.2,"volume":1352,"amount":297440,"type":"+"}]},"impliedVol":0.5035,"impliedVolPercentile":0.239},"requestUrl":"/m/hq/s/APLS/wiki","defaultTab":"wiki","newsList":[{"id":"2620251244","title":"Apellis Pharmaceuticals Is Maintained at Overweight by Cantor Fitzgerald","url":"https://stock-news.laohu8.com/highlight/detail?id=2620251244","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620251244?lang=en_us&edition=fundamental","pubTime":"2026-03-18 21:50","pubTimestamp":1773841800,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/APLS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 18, 2026 09:50 ET (13:50 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","LU1093756168.USD","BK4588","BK4585","APLS","BK4139","LU1093756325.SGD"],"gpt_icon":0},{"id":"2619878112","title":"Apellis Pharmaceuticals Initiated at Buy by Roth Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2619878112","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619878112?lang=en_us&edition=fundamental","pubTime":"2026-03-14 02:00","pubTimestamp":1773424800,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/APLS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 13, 2026 14:00 ET (18:00 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APLS","LU1093756168.USD","LU1093756325.SGD","BK4588","BK4139","BK4585","BK4505"],"gpt_icon":0},{"id":"2619162297","title":"Apellis initiated with a Buy at Roth Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2619162297","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619162297?lang=en_us&edition=fundamental","pubTime":"2026-03-13 16:30","pubTimestamp":1773390628,"startTime":"0","endTime":"0","summary":"Roth Capital analyst Adam Walsh initiated coverage of Apellis (APLS) with a Buy rating and $31 price target The firm sees strong underlying demand ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/apellis-initiated-with-a-buy-at-roth-capital-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/apellis-initiated-with-a-buy-at-roth-capital-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","LU1093756325.SGD","APLS","LU1093756168.USD","BK4505","BK4585","BK4139"],"gpt_icon":0},{"id":"2616372190","title":"Apellis Pharmaceuticals Files Initial Beneficial Ownership Statement for Director Mikael Dolsten","url":"https://stock-news.laohu8.com/highlight/detail?id=2616372190","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616372190?lang=en_us&edition=fundamental","pubTime":"2026-03-04 05:57","pubTimestamp":1772575075,"startTime":"0","endTime":"0","summary":"Apellis Pharmaceuticals, Inc. filed an Initial Statement of Beneficial Ownership  reporting Mikael Dolsten as a director. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Apellis Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 03, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260303:nNDL7c6ZL8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1093756168.USD","APLS","LU1093756325.SGD","BK4588","BK4139","BK4505","BK4585"],"gpt_icon":0},{"id":"2616339086","title":"Apellis Names Former Pfizer CSO Mikael Dolsten to Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2616339086","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616339086?lang=en_us&edition=fundamental","pubTime":"2026-03-02 20:00","pubTimestamp":1772452855,"startTime":"0","endTime":"0","summary":"Apellis Pharmaceuticals Inc. said Mikael Dolsten, M.D., Ph.D., joined its board of directors effective March 1. Dolsten most recently served at Pfizer for more than 16 years as chief scientific officer and president of worldwide research, development and medical.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260302:nNDLSMQmY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LU0234572021.USD","BK4568","LU0321505868.SGD","LU0225771236.USD","LU0868494617.USD","BK4550","IE00BKPKM429.USD","LU1894683264.USD","BK4534","LU2095319765.USD","BK4585","SG9999014021.USD","IE00BLSP4239.USD","LU0058720904.USD","BK4139","SG9999003800.SGD","BK4581","LU1894683348.USD","BK4533","SG9999011175.SGD","SGXZ57979304.SGD","BK4592","SG9999014013.SGD","LU0321505439.SGD","SG9999002232.USD","LU1883839398.USD","LU1057294990.SGD","APLS","LU1066053197.SGD","LU1093756168.USD","IE00B19Z3B42.SGD","LU2210150020.SGD","SG9999014005.SGD","SG9999013999.USD","IE000M9KFDE8.USD","LU0289739699.SGD","SG9999002224.SGD","SG9999014039.USD","IE00B3QW5Z07.USD","LU0306806265.USD","BK4588","IE00BLSP4452.SGD","LU0225284248.USD","IE00B19Z3581.USD","IE0002270589.USD","BK4112","BK4599","LU0122379950.USD","IE00BGHQF748.EUR","BK4505","SG9999001176.SGD","IE00B64PRP62.GBP","LU0314104364.USD","SG9999001176.USD","LU1066051498.USD","LU0306807586.USD","LU1023059063.AUD","LU0456855351.SGD","LU1093756325.SGD","LU0985481810.HKD","IE00BBT3K403.USD","LU0170899867.USD","LU2210149790.SGD"],"gpt_icon":0},{"id":"2616339728","title":"Apellis Announces Mikael Dolsten, M.d., Ph.d., to Join Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2616339728","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616339728?lang=en_us&edition=fundamental","pubTime":"2026-03-02 20:00","pubTimestamp":1772452804,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260302:nTUA1VGYCX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4505","BK4585","LU1093756168.USD","BK4588","APLS","LU1093756325.SGD","BK4139"],"gpt_icon":0},{"id":"2614129518","title":"A Look At Apellis Pharmaceuticals (APLS) Valuation After 2025 Results And Softer Syfovre Growth Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2614129518","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614129518?lang=en_us&edition=fundamental","pubTime":"2026-02-28 21:27","pubTimestamp":1772285245,"startTime":"0","endTime":"0","summary":"Apellis Pharmaceuticals (APLS) has drawn fresh attention after reporting fourth quarter and full year 2025 results, showing a move to full year profitability along with a weaker fourth quarter and a more cautious outlook for Syfovre.\nSee our latest analysis for Apellis Pharmaceuticals.\nThe recent earnings release and more cautious commentary around Syfovre seem to have weighed on sentiment, with a 7 day share price return of 6.01% decline and a year to date share price return of 19.03%...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-apls/apellis-pharmaceuticals/news/a-look-at-apellis-pharmaceuticals-apls-valuation-after-2025","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-apls/apellis-pharmaceuticals/news/a-look-at-apellis-pharmaceuticals-apls-valuation-after-2025","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4505","BK4585","LU1093756168.USD","BK4588","APLS","LU1093756325.SGD","BK4139"],"gpt_icon":0},{"id":"1188667814","title":"Stock Track | Apellis Pharmaceuticals Plummets 5.17% Intraday Following Analyst Price Target Cuts and Neutral Ratings","url":"https://stock-news.laohu8.com/highlight/detail?id=1188667814","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1188667814?lang=en_us&edition=fundamental","pubTime":"2026-02-25 23:53","pubTimestamp":1772034817,"startTime":"0","endTime":"0","summary":"Apellis Pharmaceuticals Inc. (APLS) saw its stock price plummet by 5.17% during intraday trading on Wednesday, reflecting negative market sentiment toward the biopharmaceutical company.The sharp...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["APLS"],"gpt_icon":0},{"id":"2614940080","title":"Apellis price target lowered to $18 from $20 at Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2614940080","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614940080?lang=en_us&edition=fundamental","pubTime":"2026-02-25 21:36","pubTimestamp":1772026613,"startTime":"0","endTime":"0","summary":"Wedbush lowered the firm’s price target on Apellis (APLS) to $18 from $20 and keeps a Neutral rating on the shares. Overall, the Q4 report from Ape...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/apellis-price-target-lowered-to-18-from-20-at-wedbush-thefly-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/apellis-price-target-lowered-to-18-from-20-at-wedbush-thefly-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4505","BK4585","APLS","LU1093756168.USD","BK4139","LU1093756325.SGD"],"gpt_icon":0},{"id":"2614082173","title":"Cantor Fitzgerald Remains a Buy on Apellis Pharmaceuticals (APLS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2614082173","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614082173?lang=en_us&edition=fundamental","pubTime":"2026-02-25 20:56","pubTimestamp":1772024188,"startTime":"0","endTime":"0","summary":"Cantor Fitzgerald analyst Steven Seedhouse maintained a Buy rating on Apellis Pharmaceuticals yesterday and set a price target of $35.00. The compa...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/cantor-fitzgerald-remains-a-buy-on-apellis-pharmaceuticals-apls-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/cantor-fitzgerald-remains-a-buy-on-apellis-pharmaceuticals-apls-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4505","LU1093756168.USD","BK4588","BK4585","APLS","BK4139","LU1093756325.SGD"],"gpt_icon":0},{"id":"2614089070","title":"Apellis Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2614089070","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614089070?lang=en_us&edition=fundamental","pubTime":"2026-02-25 20:01","pubTimestamp":1772020860,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/APLS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 25, 2026 07:01 ET (12:01 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4585","APLS","LU1093756325.SGD","BK4139","BK4505","LU1093756168.USD"],"gpt_icon":0},{"id":"2614088827","title":"Barclays Keeps Their Hold Rating on Apellis Pharmaceuticals (APLS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2614088827","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614088827?lang=en_us&edition=fundamental","pubTime":"2026-02-25 18:07","pubTimestamp":1772014047,"startTime":"0","endTime":"0","summary":"In a report released today, Eliana Merle from Barclays maintained a Hold rating on Apellis Pharmaceuticals, with a price target of $24.00. Merle co...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/barclays-keeps-their-hold-rating-on-apellis-pharmaceuticals-apls-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/barclays-keeps-their-hold-rating-on-apellis-pharmaceuticals-apls-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["APLS"],"gpt_icon":0},{"id":"2614749967","title":"Wedbush Adjusts Apellis Pharmaceuticals Price Target to $18 From $20, Maintains Neutral Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2614749967","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614749967?lang=en_us&edition=fundamental","pubTime":"2026-02-25 01:21","pubTimestamp":1771953683,"startTime":"0","endTime":"0","summary":"Apellis Pharmaceuticals (APLS) has an average rating of overweight and mean price target of $33.95, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["APLS","BK4139","LU1093756168.USD","LU1093756325.SGD","BK4505","BK4588","BK4585"],"gpt_icon":0},{"id":"2614745249","title":"Analysts Are Bullish on Top Healthcare Stocks: Palisade Bio (PALI), Apellis Pharmaceuticals (APLS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2614745249","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614745249?lang=en_us&edition=fundamental","pubTime":"2026-02-25 00:10","pubTimestamp":1771949426,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Palisade Bio (PALI – Research Report) and Apellis Ph...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-palisade-bio-pali-apellis-pharmaceuticals-apls-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-palisade-bio-pali-apellis-pharmaceuticals-apls-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["APLS","LU0128526141.USD","BK4581","BK4112","BK4007","LU1093756168.USD","BLSX","XBI","LU1093756325.SGD","BK4588","LU0029874061.USD","BK4137","BK4505","BLSG","BK4585","LABU","PALI","BK4139"],"gpt_icon":0},{"id":"1117776674","title":"Stock Track | Apellis Pharmaceuticals Plummets 6.90% Intraday on Q4 Earnings Miss and Widening Losses","url":"https://stock-news.laohu8.com/highlight/detail?id=1117776674","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1117776674?lang=en_us&edition=fundamental","pubTime":"2026-02-24 22:35","pubTimestamp":1771943726,"startTime":"0","endTime":"0","summary":"Apellis Pharmaceuticals Inc. (NASDAQ: APLS) saw its stock price plummet 6.90% during Tuesday's intraday trading session.The sharp decline followed the release of the company's fourth-quarter 2025...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["APLS"],"gpt_icon":0},{"id":"2613808716","title":"Apellis Q4 product revenue driven by SYFOVRE sales","url":"https://stock-news.laohu8.com/highlight/detail?id=2613808716","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613808716?lang=en_us&edition=fundamental","pubTime":"2026-02-24 20:12","pubTimestamp":1771935175,"startTime":"0","endTime":"0","summary":"Apellis Q4 product revenue driven by SYFOVRE salesOverviewBiopharmaceutical company reported Q4 product revenue of $190 mln, driven by SYFOVRE salesNet income for 2025 was $22 mln, compared to a net l","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nL1N3ZK0HZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","APLS","BK4588","BK4505","LU1093756168.USD","LU1093756325.SGD","BK4585"],"gpt_icon":0},{"id":"2613891716","title":"Earnings Flash (APLS) Apellis Pharmaceuticals Posts Q4 EPS $0.47, vs. FactSet Est of $0.39 Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2613891716","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613891716?lang=en_us&edition=fundamental","pubTime":"2026-02-24 20:09","pubTimestamp":1771934993,"startTime":"0","endTime":"0","summary":"Earnings Flash (APLS) Apellis Pharmaceuticals Posts Q4 EPS $0.47, vs. FactSet Est of $0.39 Loss","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["APLS"],"gpt_icon":0},{"id":"2613715055","title":"Apellis Pharmaceuticals Q4 EPS $(0.47) Misses $(0.38) Estimate, Sales $199.913M Beat $199.222M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2613715055","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613715055?lang=en_us&edition=fundamental","pubTime":"2026-02-24 20:07","pubTimestamp":1771934821,"startTime":"0","endTime":"0","summary":"Apellis Pharmaceuticals (NASDAQ:APLS) reported quarterly losses of $(0.47) per share which missed the analyst consensus estimate of $(0.38) by 23.36 percent. This is a 62.07 percent decrease over losses of $(0.29) per","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/02/50809199/apellis-pharmaceuticals-q4-eps-0-47-misses-0-38-estimate-sales-199-913m-beat-199-222m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4585","LU1093756325.SGD","APLS","BK4505","BK4139","LU1093756168.USD"],"gpt_icon":0},{"id":"2613152717","title":"BRIEF-Apellis Pharmaceuticals Q4 Basic EPS USD 0.47","url":"https://stock-news.laohu8.com/highlight/detail?id=2613152717","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613152717?lang=en_us&edition=fundamental","pubTime":"2026-02-24 20:05","pubTimestamp":1771934745,"startTime":"0","endTime":"0","summary":"BRIEF-Apellis Pharmaceuticals Q4 Basic EPS USD 0.47\n\n\nFeb 24 (Reuters) - Apellis Pharmaceuticals Q4 operating expenses USD 251.055 million.\n\nQ4 product revenue USD 190.341 million\nQ4 net income USD -58.951 million\nQ4 operating income USD -51.142 million","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nPLXA9184B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4505","BK4585","APLS","LU1093756168.USD","BK4139","LU1093756325.SGD"],"gpt_icon":0},{"id":"2613715497","title":"Apellis Pharmaceuticals Q4 Operating Income USD -51.142 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2613715497","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613715497?lang=en_us&edition=fundamental","pubTime":"2026-02-24 20:05","pubTimestamp":1771934701,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nPLXA9184B:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4505","BK4585","BK4139","BK4588","LU1093756168.USD","APLS","LU1093756325.SGD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.apellis.com","stockEarnings":[{"period":"1week","weight":-0.0228},{"period":"1month","weight":-0.1669},{"period":"3month","weight":-0.271},{"period":"6month","weight":-0.219},{"period":"1year","weight":-0.2757},{"period":"ytd","weight":-0.2846}],"compareEarnings":[{"period":"1week","weight":-0.0094},{"period":"1month","weight":-0.0338},{"period":"3month","weight":-0.0305},{"period":"6month","weight":-0.0059},{"period":"1year","weight":0.1634},{"period":"ytd","weight":-0.0324}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.444444,"avgChangeRate":-0.03559},{"month":2,"riseRate":0.555556,"avgChangeRate":0.020983},{"month":3,"riseRate":0.444444,"avgChangeRate":0.003939},{"month":4,"riseRate":0.625,"avgChangeRate":0.039768},{"month":5,"riseRate":0.375,"avgChangeRate":-0.036849},{"month":6,"riseRate":0.75,"avgChangeRate":0.072936},{"month":7,"riseRate":0.625,"avgChangeRate":-0.050758},{"month":8,"riseRate":0.875,"avgChangeRate":0.155594},{"month":9,"riseRate":0.125,"avgChangeRate":-0.147812},{"month":10,"riseRate":0.375,"avgChangeRate":0.006953},{"month":11,"riseRate":0.625,"avgChangeRate":0.128375},{"month":12,"riseRate":0.777778,"avgChangeRate":0.130311}],"exchange":"NASDAQ","name":"Apellis Pharmaceuticals Inc.","nameEN":"Apellis Pharmaceuticals Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Apellis Pharmaceuticals Inc.(APLS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Apellis Pharmaceuticals Inc.(APLS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Apellis Pharmaceuticals Inc.,APLS,Apellis Pharmaceuticals Inc.股票,Apellis Pharmaceuticals Inc.股票老虎,Apellis Pharmaceuticals Inc.股票老虎国际,Apellis Pharmaceuticals Inc.行情,Apellis Pharmaceuticals Inc.股票行情,Apellis Pharmaceuticals Inc.股价,Apellis Pharmaceuticals Inc.股市,Apellis Pharmaceuticals Inc.股票价格,Apellis Pharmaceuticals Inc.股票交易,Apellis Pharmaceuticals Inc.股票购买,Apellis Pharmaceuticals Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Apellis Pharmaceuticals Inc.(APLS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Apellis Pharmaceuticals Inc.(APLS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}